SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Nilutamide

Item No. 23953

CAS Registry No.:	63612-50-0
Formal Name:	5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl) phenyl]-2,4-imidazolidinedione
Synonym:	RU-23908
MF:	$C_{12}H_{10}F_3N_3O_4$
FW:	317.2
Purity:	≥98%
UV/Vis.:	λ_{max}: 262 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Nilutamide is supplied as a crystalline solid. A stock solution may be made by dissolving the nilutamide in the solvent of choice. Nilutamide is soluble in organic solvents such as ethanol and DMSO, which should be purged with an inert gas. The solubility of nilutamide in these solvents is approximately 25 mM. Nilutamide is also slightly soluble in chloroform and methanol.

Description

Nilutamide is a non-steroidal antiandrogen that is an antagonist of the androgen receptor.[1] It reverses testosterone-induced increases in cell proliferation with an IC_{50} value of 412 nM in mouse mammary carcinoma cells *in vitro*.[2] It has antiandrogenic activity in both intact and castrated rats, inhibiting testosterone propionate-induced prostate growth when administered at a dose of 2.5 mg/kg.[3] Formulations containing nilutamide have been used in combination with surgical castration in the treatment of metastatic prostate cancer.

References

1. Signh, S.M., Gauthier, S., and Labrie, F. Androgen receptor antagonists (antiandrogens): Structure-activity relationships. *Curr. Med. Chem.* **7(2)**, 211-247 (2000).
2. Simard, J., Singh, S.M., and Labrie, F. Comparison of *in vitro* effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. *Urology* **49(4)**, 580-586 (1997).
3. Wakeling, A.E., Furr, B.J.A., Glen, A.T., *et al.* Receptor binding and biological activity of steroidal and nonsteroidal antiandrogens. *J. Steroid Biochem.* **15**, 355-359 (1981).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM